Shandong Buchang Pharmaceuticals' subsidiary signs a technology service contract with WuXi AppTec

Shandong Buchang Pharmaceuticals (603858.SH) announced that its controlling subsidiary, Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. (hereinafter referred to as "Luzhou Buchang"), recently signed a "Technical Service Contract" with Suzhou Wuxi AppTec Pharmaceutical Development Co., Ltd. (hereinafter referred to as "Wuxi AppTec"), entrusting Wuxi AppTec to conduct pharmacokinetic and toxicological experiments. This agreement signed by Luzhou Buchang with a third party is beneficial for expanding the company's drug research and development capabilities and scope, to a certain extent saving time and costs of the company's clinical trials, and ensuring the smooth progress of the project.